ForteBio is now part of the Sartorius group. Click here for more


Oct 26, 2020 : AAPS 2020 PharmSci 360

Oct 26 – Nov 5, 2020

Conference | North America | Boston, MA

PharmSci 360 combines all the energy of a large scientific conference with the intimacy of a small niche meeting. It features six tracks, five of which are split equally between chemical and biomolecule drug programming. These tracks encompass many areas making the biggest headlines today. You can focus on one track for a “small meeting” experience, or move across tracks to get a multi-discipline perspective.  Learn more

Featured Presentations

Utilizing Octet Platform for Characterizing Critical Reagents in Support of Drug Development for Contemporary Biotherapeutics

Manufacturing and Analytical Characterization Track
Thursday November 5
10:30 AM – 11:30 AM EST

Ronald R. Bowsher, PhD, FAAPS
Chief Scientific Officer
B2S Life Sciences

Erica Simmons, PhD
Senior Scientist
B2S Life Sciences

Today, biotherapeutic drugs comprise a large portion of new drug candidates in Biopharma industry portfolios. In addition to the dramatic growth in the numbers of large molecule drugs, there is much increased diversity and structural complexity, including multi-domain therapeutics, non-proteins, new treatment modalities and advances in delivery systems. Furthermore, at present there is an immense effort underway to create new novel vaccines as treatments to remedy the COVID-19 pandemic. This shift to emphasis to large molecule therapeutics has generated renewed awareness for the need for innovation in the design, generation, characterization, and life cycle management of Critical Reagents to support both product development and regulated bioanalysis. This scenario requires critical reagent workflows that are easily customized, executed efficiently, versatile, have high throughput and operationally reliable. Accordingly, we have adapted the label-free optical technique of Bio-Layer Interferometry (BLI), the Octet platform provides real time analysis of biomolecular interactions as key tool in our critical reagent workflow. Accordingly, here we present two case studies utilizing BLI Octet technology for critical reagent characterization. The first study summarizes application of BLI technology combined with ELISA to investigate lot-to-lot batch differences for antibody critical reagent developed against a biologically active toxin. The second one describes the combination of ion-exchange chromatographic analysis with the BLI Octet platform to separate and analyze the receptor-binding activity of various charge variants for a fusion-protein drug substance. These two case studies exemplify the benefits from broad application of BLI in our standard workflows for characterization of custom critical reagents for modern biotherapeutics. We conclude to that use of Octet-HTX instrument is particularly beneficial, because it has afforded much increased efficiency to our operation due to increased capacity and speed.

Learning Objectives:

  • Understand how BLI Octet technology for affinity characterization antibodies can benefit critical reagent workflows, such as guiding decision-making about assay sensitivity and lot to lot comparisons
  • Benefits of mixed use of ELISA and BLI to support critical reagent comparison studies
  • Using BLI Octet technology for quality control and batch release of drug-substance

Facilitating Process Economy in GMP Applications with the Octet Platform

Manufacturing and Analytical Characterization Track
Thursday November 5
9:00 AM – 10:00 AM EST

David Apiyo, PhD
Senior Manager, Applications
ForteBio is now part of Sartorius

Using the label-free optical technique of Bio-Layer Interferometry (BLI), the Octet© platform provides real time analysis of biomolecular interactions. It relies on the robust and easy to use Dip and Read™ format, which provides faster time to results relative to technologies like ELISA and SPR. It also operates in a non-fluidic format thereby minimizing the complexity in analyte detection often seen in fluidics-based technologies such as SPR. It provides high throughput analysis, with the option of analyzing up to 96 samples simultaneously, thereby increasing analytical productivity. The Octet’s compatibility with a diverse range of sample types and ease of use together with simple workflows in assay set-up and data analysis enables it to be a suitable technology for GMP assays method development and for use in QC settings. In these environments, it can be used for lot-release and in-process testing assays amongst others.

Learning Objectives:

  • Overview of Bio-Layer Interferometry technology
  • ELISA & SPR comparison
  • GMP, GxP capabilities

Register Now

Nov 17, 2020 : Meet my Platform - Les Sciences De La Vie

Nov 17, 2020

Conference | Europe | Paris-Saclay, France

Genopole and the Department of Science invite you to the second edition of Meet My Platform to discover the potential of the region and to network with your peers.

Learn more

Nov 23, 2020 : AIS 2020 Multispecific Abs

Nov 23 – Nov 24, 2020

Conference | Europe | Congress Center Corum of Montpellier, France

This year is the 8th Antibody Industrial Symposium and an exciting program has been set up around this year’s theme: “Multispecific Abs, Ab-like molecules and adoptive cell therapy for fighting diseases”, with keynote lectures, pitch talks around new creative projects, and industrial talks from big pharmaceutical companies. We would like to take this opportunity to welcome you along and demonstrate our therapeutic antibody solutions.

Learn more

Nov 30, 2020 : World Vaccine & Immunotherapy Congress West Coast 2020

Nov 30 – Dec 3, 2020

Conference | North America | Virtual Event

Come together and join us VIRTUALLY to identify the urgent priorities for research. To mobilize, coordinate and align funding to enable the research needed to tackle this crisis and stop the outbreak, and commit with our experts how you can learn mechanisms for continuing scientific interactions and collaborations, now and beyond the congress.

We need your contribution to work together

Learn more

Dec 14, 2020 : Antibody Engineering & Therapeutics

Dec 14 - Dec 17, 2020

Conference | North America | Virtual Event

Come together Antibody Engineering & Therapeutics is the #1 antibody engineering conference for accelerating next generation antibodies to commercial success. This is where over 1,000 attendees will discover the latest science, technology, and partners in antibody engineering, immunobiology, and next generation binders.

Learn more

We use cookies to personalize content and improve your browsing experience.

We also use analytics & advertising services. To opt-out click for more information.